"Fall-risk increasing drugs are commonly prescribed to people with COPD because they experience a high number of symptoms and conditions that indicate use of these drugs," said Cara L. McDermott, ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Asthma–chronic obstructive pulmonary disease (COPD ... then to determine the best available therapy. The authors discuss the array of existing and emerging classes of drugs that could benefit ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

Although these products might confer significant advantages over the currently available treatments, there is still a huge unmet need for drugs that prevent the progression of COPD. Companies are ...

Unfortunately, these drugs don't work for everyone and ... 40 people in the world have experienced eosinophilic asthma or COPD flare-up. Under current best treatments, 30 of them will require ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

The drug – which is administered twice-daily using a nebuliser as a chronic maintenance therapy for people with COPD – achieved significant improvements on the primary endpoint of forced ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

The Swiss drug development company Windward Bio recently announced that ... TSLP has been found to play a key role in ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing drugs, according to a new study.